General Information of Drug (ID: DMRKXPT)

Drug Name
Ketoprofen Drug Info
Synonyms
Actron; Alrheumat; Alrheumum; Alrheumun; Aneol; Capisten; Dexal; Epatec; Fastum; Kefenid; Ketoprofene; Ketoprofeno; Ketoprofenum; Ketopron; Ketoprophene; Lertus; Menamin; Meprofen; Orudis; Orugesic; Oruvail; Oscorel; Profenid; Toprec; Toprek; Benzoylhydratropic Acid; Orudis KT; K 1751; RP 19583; RP19583; RU 4733; Arthril (TN); Fastum (TN); Fastum Gel (TN); Iso-K; Keto (TN); Ketoflam (TN); Ketomex (TN); Ketonal (TN); Ketoprofenas (TN); Ketoprofene (TN); Ketoprofene [INN-French]; Ketoprofeno [INN-Spanish]; Ketoprofenum (TN); Ketoprofenum [INN-Latin]; Ketorin (TN); Ketospray (TN); Lasonil (TN); M-Benzoylhydratropic acid; Oki (TN); Orudis (TN); Oruvail (TN); RP-19583; Racemic-Ketoprofen; Zon (TN); Bi-Profnid (TN); RP, 19,583; Ketoprofen (JP15/USP/INN); Ketoprofen [USAN:INN:BAN:JAN]; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Acide (benzoyl-3-phenyl)-2-propionique; Acide (benzoyl-3-phenyl)-2-propionique [French]; L'Acide (benzoyl-3-phenyl)-2-propionique; (+-)-m-Benzoylhydratropic acid; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; 2-(m-Benzoylphenyl)propionic acid; 2-[3-(benzoyl)phenyl]propanoic acid; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-[3-Benzoylphenyl]propionic acid; 3-Benzoylhydratropic acid
Indication
Disease Entry ICD 11 Status REF
Bursitis Approved [1]
Dysmenorrhea GA34.3 Approved [1]
Musculoskeletal pain MG30 Approved [2]
Pain MG30-MG3Z Phase 3 [3]
Migraine 8A80 Phase 2 [4]
Osteoarthritis FA00-FA05 Phase 1 [4]
Therapeutic Class
Analgesics
Cross-matching ID
PubChem CID
3825
ChEBI ID
CHEMBL571
CAS Number
CAS 22071-15-4
TTD Drug ID
DMRKXPT
VARIDT Drug ID
DR00690
INTEDE Drug ID
DR0907
ACDINA Drug ID
D00343

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [13]
Naproxen DMZ5RGV Bursitis Approved [14]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [15]
Indomethacin DMSC4A7 Bursitis Approved [16]
Celecoxib DM6LOQU Dysmenorrhea GA34.3 Approved [17]
Nabumetone DMAT2XH Osteoarthritis FA00-FA05 Approved [18]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [19]
Flurbiprofen DMGN4BY Osteoarthritis FA00-FA05 Approved [20]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [21]
Aminosalicylic Acid DMENSL5 Crohn disease DD70 Approved [16]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [22]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [23]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [24]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [25]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [26]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [27]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [28]
Metronidazole DMTIVEN Abscess Approved [29]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [30]
Ethanol DMDRQZU Chronic pain MG30 Approved [31]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [32]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [33]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [34]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [35]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [36]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [35]
Verapamil DMA7PEW Angina pectoris BA40 Approved [37]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [38]
Estrone DM5T6US Acne vulgaris ED80 Approved [39]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [40]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Phenoxybenzamine DM8KSQH Malignant essential hypertension BA00 Approved [41]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [42]
Trospium chloride DM32XZT Discovery agent N.A. Approved [43]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [44]
Lamivudine DMI347A Chronic HBV infection 1E51.0Z Approved [45]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [12]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [46]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [47]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [48]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [49]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [12]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [12]
Quercetin DM3NC4M Obesity 5B81 Approved [50]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [12]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [12]
Succinic acid DMDWICP Malnutrition 5B50-5B71 Approved [51]
Mefenamic acid DMK7HFI Dysmenorrhea GA34.3 Approved [12]
Probenecid DMMFWOJ Acute gonococcal cervicitis Approved [52]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [12]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [12]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [54]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [55]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [12]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [12]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [56]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [57]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [46]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [12]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [12]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [46]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [12]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [12]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [58]
Mefenamic acid DMK7HFI Dysmenorrhea GA34.3 Approved [12]
Probenecid DMMFWOJ Acute gonococcal cervicitis Approved [59]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [12]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [60]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aspirin DM672AH Acute coronary syndrome BA41 Approved [12]
Methotrexate DM2TEOL Anterior urethra cancer Approved [61]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [54]
Paclitaxel DMLB81S Breast carcinoma Approved [62]
Allopurinol DMLPAOB Gout FA25 Approved [62]
Bumetanide DMRV7H0 Congestive heart failure BD10 Approved [62]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [62]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [62]
Tetracycline DMZA017 Acne vulgaris ED80 Approved [62]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [63]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [64]
Trametinib DM2JGQ3 Melanoma 2C30 Approved [65]
Methotrexate DM2TEOL Anterior urethra cancer Approved [61]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [66]
Panobinostat DM58WKG Chronic graft versus host disease Approved [67]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [68]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [68]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [69]
Oxaprozin DM9UB0P Osteoarthritis FA00-FA05 Approved [70]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [56]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aspirin DM672AH Acute coronary syndrome BA41 Approved [71]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [11]
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [11]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [72]
Allopurinol DMLPAOB Gout FA25 Approved [73]
Ticlopidine DMO946V Acute coronary syndrome BA41 Approved [74]
Selenium DM25CGV N. A. N. A. Approved [75]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [11]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [76]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [77]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Albumin (ALB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [78]
Sulfamethoxazole DMB08GE Acute otitis media AB00 Approved [79]
Tolbutamide DM02AWV Advanced cancer 2A00-2F9Z Approved [8]
Diazepam DM08E9O Alcohol withdrawal Approved [80]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [81]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [82]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [83]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [84]
Methotrexate DM2TEOL Anterior urethra cancer Approved [85]
Quercetin DM3NC4M Obesity 5B81 Approved [86]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [75]
Fluoxetine DM3PD2C Bipolar depression Approved [11]
Cinoxacin DM4EWNS Urinary tract infection GC08 Approved [11]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [77]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [87]
Testosterone DM7HUNW Hot flushes GA30 Approved [88]
Valdecoxib DMAY7H4 Osteoarthritis FA00-FA05 Approved [11]
Testosterone enanthate DMB6871 N. A. N. A. Approved [89]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [90]
Cephalexin DMD5JU8 Acute otitis media AB00 Approved [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 4A11 (CYP4A11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clofibrate DMPC1J7 Dysbetalipoproteinemia 5C80.2 Approved [91]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [9]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [9]
Methotrexate DM2TEOL Anterior urethra cancer Approved [92]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [93]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [94]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [94]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [9]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [9]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [10]
Quercetin DM3NC4M Obesity 5B81 Approved [10]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [47]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [77]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [56]
Flufenamic Acid DMC8VNH Dysmenorrhea GA34.3 Approved [10]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [57]
Demecolcine DMCZQGK Solid tumour/cancer 2A00-2F9Z Approved [95]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [96]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [97]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [6]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Albumin (ALB) OTVMM513 ALBU_HUMAN Protein Interaction/Cellular Processes [8]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Gene/Protein Processing [9]
Dehydrogenase/reductase SDR family member 11 (DHRS11) OTU3J0ZL DHR11_HUMAN Gene/Protein Processing [10]
HLA class II histocompatibility antigen, DP alpha 1 chain (HLA-DPA1) OT7OG7Y2 DPA1_HUMAN Gene/Protein Processing [11]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1) OTVVI3UI DQB1_HUMAN Gene/Protein Processing [11]
Organic anion transporter 7 (SLC22A9) OTO4BJCC S22A9_HUMAN Gene/Protein Processing [12]
Solute carrier family 22 member 1 (SLC22A1) OT7817I4 S22A1_HUMAN Gene/Protein Processing [12]
Solute carrier family 22 member 11 (SLC22A11) OTAJLNJZ S22AB_HUMAN Gene/Protein Processing [12]
Solute carrier family 22 member 6 (SLC22A6) OTKRCBVM S22A6_HUMAN Gene/Protein Processing [12]
Solute carrier family 22 member 7 (SLC22A7) OTKTNH1W S22A7_HUMAN Gene/Protein Processing [12]

References

1 Ketoprofen FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4795).
3 Ketoprofen-induced cyclooxygenase inhibition in renal medulla and platelets of rats treated with caffeine. Pharmacology. 2001;63(4):234-9.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Probing the skin permeation of fish oil/EPA and ketoprofen-3. Effects on epidermal COX-2 and LOX. Prostaglandins Leukot Essent Fatty Acids. 2007 Jun;76(6):357-62.
6 Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis. Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):167-73.
7 Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis. Biosci Rep. 2019 May 2;39(5). pii: BSR20182105.
8 A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. J Pharm Biomed Anal. 2010 Jul 8;52(3):420-4. doi: 10.1016/j.jpba.2009.06.023. Epub 2009 Jun 18.
9 Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
10 Rabbit dehydrogenase/reductase SDR family member 11 (DHRS11): Its identity with acetohexamide reductase with broad substrate specificity and inhibitor sensitivity, different from human DHRS11. Chem Biol Interact. 2019 May 25;305:12-20. doi: 10.1016/j.cbi.2019.03.026. Epub 2019 Mar 26.
11 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
12 Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
13 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
14 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
15 Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
17 Pfizer. Product Development Pipeline. March 31 2009.
18 Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
19 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
20 Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
21 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
22 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
23 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
24 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
25 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
26 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
27 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
28 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
29 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
30 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
31 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
32 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
33 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
34 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
35 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
36 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
37 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
38 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
39 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
40 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
41 Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
42 Involvement of aryl hydrocarbon receptor in the cytotoxicity of corannulene and its derivatives. Toxicol Lett. 2020 Mar 15;321:114-121. doi: 10.1016/j.toxlet.2019.12.012. Epub 2019 Dec 9.
43 Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
44 Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
45 Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther. 2009 Apr;329(1):252-61. doi: 10.1124/jpet.108.146225. Epub 2009 Jan 13.
46 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
47 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
48 The pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by competing for ("squelching") SRC-1 coactivator. Br J Pharmacol. 2016 May;173(10):1703-15. doi: 10.1111/bph.13472. Epub 2016 Apr 8.
49 P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate. Toxicol Appl Pharmacol. 2016 Sep 1;306:27-35. doi: 10.1016/j.taap.2016.06.030. Epub 2016 Jul 1.
50 Potent Inhibitors of Organic Anion Transporters 1 and 3 From Natural Compounds and Their Protective Effect on Aristolochic Acid Nephropathy. Toxicol Sci. 2020 Jun 1;175(2):279-291. doi: 10.1093/toxsci/kfaa033.
51 Lack of efflux of diglycolic acid from proximal tubule cells leads to its accumulation and to toxicity of diethylene glycol. Toxicol Lett. 2023 Apr 15;379:48-55. doi: 10.1016/j.toxlet.2023.03.007. Epub 2023 Mar 22.
52 Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Toxicol In Vitro. 2017 Oct;44:27-35.
53 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
54 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
55 Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
56 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
57 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
58 Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. J Steroid Biochem Mol Biol. 2016 Oct;163:77-87.
59 Neonicotinoid pesticides poorly interact with human drug transporters. J Biochem Mol Toxicol. 2019 Oct;33(10):e22379. doi: 10.1002/jbt.22379. Epub 2019 Jul 31.
60 Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884. doi: 10.1007/s00204-017-2008-8. Epub 2017 Jun 9.
61 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
62 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
63 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
64 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
65 Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma. Br J Dermatol. 2019 Feb;180(2):346-356. doi: 10.1111/bjd.17333. Epub 2018 Nov 25.
66 TAp73 knockout mice show morphological and functional nervous system defects associated with loss of p75 neurotrophin receptor. Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18952-7. doi: 10.1073/pnas.1221172110. Epub 2013 Nov 4.
67 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
68 A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother Pharmacol. 2008 Feb;61(2):203-14. doi: 10.1007/s00280-007-0462-3. Epub 2007 Apr 20.
69 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
70 The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
71 The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin Exp Allergy. 2005 Mar;35(3):339-44. doi: 10.1111/j.1365-2222.2004.02197.x.
72 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
73 A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunogenet. 2011 Aug;38(4):303-9. doi: 10.1111/j.1744-313X.2011.01011.x. Epub 2011 May 4.
74 Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 2008 Feb;8(1):29-33. doi: 10.1038/sj.tpj.6500442. Epub 2007 Mar 6.
75 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
76 Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
77 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
78 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
79 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
80 The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
81 Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies. Chem Biol Interact. 2015 Dec 5;242:235-46. doi: 10.1016/j.cbi.2015.10.006. Epub 2015 Oct 22.
82 Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
83 Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates. J Chromatogr A. 2011 Apr 15;1218(15):2072-8. doi: 10.1016/j.chroma.2010.09.070. Epub 2010 Oct 16.
84 [Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
85 Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues. Toxicol Sci. 2016 Dec;154(2):354-367. doi: 10.1093/toxsci/kfw169. Epub 2016 Sep 7.
86 Covalent binding of the flavonoid quercetin to human serum albumin. J Agric Food Chem. 2005 May 18;53(10):4194-7. doi: 10.1021/jf050061m.
87 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
88 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
89 Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
90 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
91 Regulation of CYP4A expression by bezafibrate in primary culture of rat and human hepatocytes: interspecies difference and influence of N-acetylcysteine. Toxicol In Vitro. 2009 Oct;23(7):1259-67.
92 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
93 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
94 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
95 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
96 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
97 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.